

# Lourdes Maria Perez-Chada

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1304648/publications.pdf>

Version: 2024-02-01

36  
papers

537  
citations

1040056

9  
h-index

713466

21  
g-index

38  
all docs

38  
docs citations

38  
times ranked

764  
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient Perspectives on the Use of Artificial Intelligence for Skin Cancer Screening. <i>JAMA Dermatology</i> , 2020, 156, 501.	4.1	135
2	Comorbidities associated with psoriatic arthritis: Review and update. <i>Clinical Immunology</i> , 2020, 214, 108397.	3.2	83
3	TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019, 4, 70-80.	0.7	67
4	Measuring fatigue: a meta-review. <i>International Journal of Dermatology</i> , 2021, 60, 1053-1069.	1.0	26
5	Impaired Coronary Vasodilator Reserve and Adverse Prognosis in Patients With Systemic Inflammatory Disorders. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 2212-2220.	5.3	24
6	Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study. <i>Nature Reviews Rheumatology</i> , 2021, 17, 238-243.	8.0	23
7	Bridging the Gaps in the Care of Psoriasis and Psoriatic Arthritis: the Role of Combined Clinics. <i>Current Rheumatology Reports</i> , 2018, 20, 76.	4.7	22
8	Coronary microvascular dysfunction in patients with psoriasis. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 37-42.	2.1	18
9	Psoriatic arthritis and the dermatologist: An approach to screening and clinical evaluation. <i>Clinics in Dermatology</i> , 2018, 36, 551-560.	1.6	15
10	Achieving international consensus on the assessment of psoriatic arthritis in psoriasis clinical trials: an International Dermatology Outcome Measures (IDEOM) initiative. <i>Archives of Dermatological Research</i> , 2018, 310, 701-710.	1.9	10
11	Are Your Patients Satisfied A Systematic Review of Treatment Satisfaction Measures in Psoriasis. <i>Dermatology</i> , 2018, 234, 157-165.	2.1	10
12	Treatment of immune checkpoint inhibitor-mediated psoriasis: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 399-400.	1.2	9
13	Development of a working core outcome set for cutaneous lupus erythematosus: a practical approach to an urgent unmet need. <i>Lupus Science and Medicine</i> , 2021, 8, e000529.	2.7	9
14	Report of the Skin Research Working Groups From the GRAPPA 2020 Annual Meeting. <i>Journal of Rheumatology</i> , 2021, , jrheum.201668.	2.0	8
15	Investigator and Patient Global Assessment Measures for Psoriasis Clinical Trials: A Systematic Review on Measurement Properties from the International Dermatology Outcome Measures (IDEOM) Initiative. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 323-338.	6.7	6
16	Examination of Treatment Satisfaction Instruments in Psoriasis: 2017 Results from the Psoriasis Working Group of the International Dermatology Outcome Measures (IDEOM). <i>Dermatology</i> , 2021, 237, 151-157.	2.1	6
17	Hidradenitis suppurativa and sleep disorders: a population-based study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e520-e522.	2.4	6
18	Increased prevalence of sleep disturbance in psoriatic arthritis is associated with inflammatory and non-inflammatory measures. <i>Scandinavian Journal of Rheumatology</i> , 2022, , 1-9.	1.1	6

#	ARTICLE	IF	CITATIONS
19	Older adults on systemic treatment for psoriasis and risk of infection: a propensity score-matched population-based study. <i>British Journal of Dermatology</i> , 2020, 183, 564-566.	1.5	5
20	The National Psoriasis Foundation psoriasis treatment targets in real-world patients: prevalence and association with patient-reported outcomes in the Corrona Psoriasis Registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2051-2058.	2.4	5
21	International Dermatology Outcome Measures (IDEOM) Group 2016 New York Meeting: Meeting Summary and Data from the Psoriasis Working Group. <i>Journal of Drugs in Dermatology</i> , 2017, 16, 770-777.	0.8	5
22	Measuring psoriatic arthritis symptoms: A core domain in psoriasis clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 54-61.	1.2	4
23	Hidradenitis suppurativa odour and drainage scale: a novel method for evaluating odour and drainage in patients with hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2021, 184, 772-774.	1.5	4
24	Leveraging behavioral economics to promote treatment adherence: A primer for the practicing dermatologist. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 1075-1080.	1.2	4
25	International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting. <i>Dermatology</i> , 2022, 238, 430-437.	2.1	4
26	Physician Perspectives on the Effect of Topical Steroid Costs on Patients and Proposed Solutions. <i>JAMA Dermatology</i> , 2022, 158, 79.	4.1	4
27	Hepatitis B and C among patients with hidradenitis suppurativa: a population-based study. <i>International Journal of Dermatology</i> , 2022, 61, 84-88.	1.0	3
28	Psoriasis and COVID-19: a multifactorial consideration. <i>Journal of Dermatological Treatment</i> , 2020, , 1-1.	2.2	2
29	Measurement properties of instruments assessing psoriatic arthritis symptoms for psoriasis clinical trials: a systematic literature review. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 267-283.	3.0	2
30	Low gene expression of TNF, IL17A, IL23A, and IL12B in tumors: A safety surrogate to predict cancer survival associated with biologic therapies. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 249-252.	1.2	2
31	The association between schizophrenia spectrum disorders and psoriasis: a large-scale population-based case-control study. <i>British Journal of Dermatology</i> , 2021, 185, 443-445.	1.5	2
32	Report of the Skin Research Workgroups from the GRAPPA 2018 Annual Meeting. <i>Journal of Rheumatology</i> , 2019, 95, 28-32.	2.0	2
33	Report from the International Dermatology Outcome Measures Initiative. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2020, 20, S80-S83.	0.8	1
34	Certolizumab-Induced Paradoxical Psoriatic Alopecia. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 86-92.	0.7	1
35	Defining Psoriasis Remission Based on Histopathologic and Molecular Criteria: A Systematic Literature Review. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2026-2029.e4.	0.7	0
36	Report of the Skin Research Working Groups from the GRAPPA 2021 Annual Meeting. <i>Journal of Rheumatology</i> , 2022, , jrheum.211328.	2.0	0